Glenmark begins distribution of morphine in the US
This article was originally published in Scrip
Glenmark Generics' US subsidiary has commenced distribution of morphine sulfate oral concentrate solution 20mg/ml in the US. Glenmark has a licensing agreement with a US-based pharmaceutical development company for the product. The product is available in three presentations and is indicated for the relief of moderate to severe pain. Sales for the product for the 12 months ended June 2008 were more than $15 million. The product complements Glenmark's current portfolio of both oral solid and oral liquid pain management products, which are manufactured for Glenmark in the US through a partnership and are distributed from Glenmark Generics' warehouse in New Jersey. Glenmark currently has 36 products authorised for distribution in the US.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.